跳至主要内容
临床试验/EUCTR2019-000946-37-FR
EUCTR2019-000946-37-FR进行中(未招募)1 期

Molecular imaging exploration of ocular angiogenic activity and evaluation of its relevance in the therapeutic follow-up of AMD patients. - DMLA-RGD

Assistance Publique-Hôpitaux de Marseille0 个研究点目标入组 20 人开始时间: 2020年8月10日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age = 18 years old, membership of a social security scheme.
  • - Signature of informed consent,
  • - Subject with unilaterally affected AMD with at least 1 focus of choroidal neovascularization objectified in OCT, naïve to any antiangiogenic treatment.
  • - Initial workup including at least OCT and visual acuity measurement, no more than 1 month old at the time of the 68Ga-NODAGA-RGD PET scan.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • - Pregnant or breastfeeding women, as a radiation protection measure.
  • - Subjects under 18 years of age and/or not affiliated to a social security scheme.
  • - Subjects with bilateral AMD.
  • - Subjects presenting an AMD without neovascularization focus as determined by the classical diagnostic scheme.
  • - Subjects who have already been treated with antiangiogenic therapy.
  • - Subjects with any other ophthalmologic pathology.
  • - Monophthalmic subjects.

研究者

相似试验